Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation

6 Months Ended

Jun. 30, 2022

Note 12 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended			Six months ended
		June 30,			June 30,
	2022		2021		2022		2021
Research and development	$	2,033	$	2,512	$	4,556	$	4,887
General and administrative		3,012		2,937		6,075		5,896
	$	5,045	$	5,449	$	10,631	$	10,783

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended			Six months ended
		June 30,			June 30,
	2022		2021		2022		2021
Number of options over ordinary shares granted		1,735,488		918,048		24,611,952		15,721,104
Weighted average fair value of ordinary shares options	$	0.25	$	0.65	$	0.41	$	0.75
Number of additional options with a nominal exercise price granted		3,361,728		1,995,456		21,050,160		14,659,248
Weighted average fair value of options with a nominal exercise price	$	0.34	$	0.88	$	0.55	$	1.01